Zydus Lifesciences Ltd. has announced the launch of ANYRA™, India’s first indigenously developed biosimilar of Aflibercept 2 mg, aimed at advancing ophthalmic care. The drug is indicated for severe conditions like wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). This launch reinforces Zydus’s commitment to making high-quality, affordable biologics accessible, addressing the significant patient pool in India suffering from vision-threatening retinal diseases.
Zydus Launches India’s First Indigenous Aflibercept Biosimilar
Zydus Lifesciences Ltd. has announced the commercial launch of ANYRA™, its biosimilar version of Aflibercept 2 mg. This marks a significant milestone as it is India’s first indigenously developed biosimilar for this critical molecule. The launch underscores Zydus’s strategic focus on providing high-quality, affordable advanced biologics to the Indian market.
Therapeutic Indications and Patient Impact
ANYRA™ is indicated for treating several leading causes of vision impairment. These include neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV).
The company highlighted the massive patient burden in India, noting that over 100 million people live with diabetes, leading to an estimated 7–8 million individuals suffering from Diabetic Retinopathy (DR). The ongoing need for timely anti-VEGF therapy to prevent irreversible vision loss makes affordability and continuity of treatment crucial concerns that ANYRA™ aims to address.
Company Commitment to Accessibility
Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd., stated that the launch of ANYRA™ is a “transformative step for affordable retinal care in India.” By delivering a high-quality, indigenously developed product, Zydus is expanding access to critical therapies.
Zydus currently possesses India’s largest biosimilar portfolio, encompassing more than 13 biosimilars and complex biologic molecules manufactured entirely in the country. The company maintains end-to-end capabilities covering cell line research, process engineering, clinical trials, manufacturing, and regulatory approvals for its biologics pipeline.
Source: BSE
